TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN
Antitumor effects of the toll-like receptor 7 (TLR7) agonist, 852A, were evaluated. Supernatants from human peripheral blood mononuclear cells (PBMC) stimulated with 852A inhibited the proliferation of tumor cell lines Hs294T and 769-P but had no effect on others (786-O and Caki-1). Because addition...
Gespeichert in:
| Veröffentlicht in: | Journal of interferon & cytokine research 2008-04, Vol.28 (4), p.253-263 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 263 |
|---|---|
| container_issue | 4 |
| container_start_page | 253 |
| container_title | Journal of interferon & cytokine research |
| container_volume | 28 |
| creator | Inglefield, Jon R Dumitru, Calin Dan Alkan, Sefik S Gibson, Sheila J Lipson, Kenneth E Tomai, Mark A Larson, Chris J Vasilakos, John P |
| description | Antitumor effects of the toll-like receptor 7 (TLR7) agonist, 852A, were evaluated. Supernatants from human peripheral blood mononuclear cells (PBMC) stimulated with 852A inhibited the proliferation of tumor cell lines Hs294T and 769-P but had no effect on others (786-O and Caki-1). Because addition of 852A directly to the Hs294T cells did not inhibit their proliferation, the mechanism(s) of inhibition of tumor cell proliferation was investigated. Low nanomolar concentrations of 852A stimulated the production of interferon-alpha (IFN-alpha), IFN-inducible protein-10 (IP-10), interleukin-1 receptor antagonist (IL-1Ra), monocyte chemotactic protein-1 (MCP-1), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from human PBMCs. Cytokines stimulated by submicromolar concentrations of 852A were sufficient to inhibit Hs294T proliferation. At higher concentrations (3-30 microM), 852A induced the production of IL-12p70, IL-18, and IFN-gamma. PBMC cultures depleted of plasmacytoid dendritic cells (pDC) did not produce IFN-alpha, and their conditioned medium did not inhibit Hs294T proliferation. Anti-IFN-alpha/beta receptor (IFNAR) and anti-IFN-alpha antibodies partially abrogated Hs294T proliferation inhibition by 852A-stimulated PBMC supernatants, whereas separate neutralization of TRAIL, tumor necrosis factor-alpha (TNF-alpha, IFN-gamma, IFN-beta, or IFN-omega had no effect. In vivo, six doses of 852A administration significantly delayed the onset of lung colonies in a B16 melanoma model. Thus, the results demonstrate that the TLR7 agonist 852A inhibits in vitro proliferation of some tumor cells in a pDC-dependent and IFN-alpha-dependent manner and can delay tumor growth in vivo. |
| doi_str_mv | 10.1089/jir.2007.0097 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_69146700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A179661104</galeid><sourcerecordid>A179661104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-2b2502a3a6b1e5fe26fd48e4efee5d5757812caad8e418685e49e307f739fa4d3</originalsourceid><addsrcrecordid>eNqFktGL1DAQxoso3nn66KsEBd-6TtKmSR6Xw9OFRUHO55BtJmeWNqlJ-7D_ventgiiC5CGZmd83TJKvql5T2FCQ6sPRpw0DEBsAJZ5U15RzUYu240_LGYSqlQJxVb3I-QgAnWTqeXVFZdsoCs11Nd_vvwliHmLweSaSsy3x4Yc_-NnHQKIj8zLGRHocBjKlOHiHyTzWfCYWJwwWw0xKPA0mj6Y_zdHbUgk2lR79ozITEyyZTxOSHdndfXlZPXNmyPjqst9U3-8-3t9-rvdfP-1ut_u6b5SYa3ZgHJhpTHegyB2yztlWYosOkVsuuJCU9cbYkqOykxxbhQ0IJxrlTGubm-r9uW-Z_OeCedajz-tAJmBcsu4UbTsB8F-QgaBSKlnAt3-Bx7ikUC6hWXl54EqxAr07Qw9mQO2Di3My_dpRb6lQXUcptIXa_IMqy-Lo-xjQ-ZL_Q1CfBX2KOSd0ekp-NOmkKejVC7p4Qa9e0KsXCv_mMutyGNH-pi-f3_wC1litdQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>215505992</pqid></control><display><type>article</type><title>TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Inglefield, Jon R ; Dumitru, Calin Dan ; Alkan, Sefik S ; Gibson, Sheila J ; Lipson, Kenneth E ; Tomai, Mark A ; Larson, Chris J ; Vasilakos, John P</creator><creatorcontrib>Inglefield, Jon R ; Dumitru, Calin Dan ; Alkan, Sefik S ; Gibson, Sheila J ; Lipson, Kenneth E ; Tomai, Mark A ; Larson, Chris J ; Vasilakos, John P</creatorcontrib><description>Antitumor effects of the toll-like receptor 7 (TLR7) agonist, 852A, were evaluated. Supernatants from human peripheral blood mononuclear cells (PBMC) stimulated with 852A inhibited the proliferation of tumor cell lines Hs294T and 769-P but had no effect on others (786-O and Caki-1). Because addition of 852A directly to the Hs294T cells did not inhibit their proliferation, the mechanism(s) of inhibition of tumor cell proliferation was investigated. Low nanomolar concentrations of 852A stimulated the production of interferon-alpha (IFN-alpha), IFN-inducible protein-10 (IP-10), interleukin-1 receptor antagonist (IL-1Ra), monocyte chemotactic protein-1 (MCP-1), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from human PBMCs. Cytokines stimulated by submicromolar concentrations of 852A were sufficient to inhibit Hs294T proliferation. At higher concentrations (3-30 microM), 852A induced the production of IL-12p70, IL-18, and IFN-gamma. PBMC cultures depleted of plasmacytoid dendritic cells (pDC) did not produce IFN-alpha, and their conditioned medium did not inhibit Hs294T proliferation. Anti-IFN-alpha/beta receptor (IFNAR) and anti-IFN-alpha antibodies partially abrogated Hs294T proliferation inhibition by 852A-stimulated PBMC supernatants, whereas separate neutralization of TRAIL, tumor necrosis factor-alpha (TNF-alpha, IFN-gamma, IFN-beta, or IFN-omega had no effect. In vivo, six doses of 852A administration significantly delayed the onset of lung colonies in a B16 melanoma model. Thus, the results demonstrate that the TLR7 agonist 852A inhibits in vitro proliferation of some tumor cells in a pDC-dependent and IFN-alpha-dependent manner and can delay tumor growth in vivo.</description><identifier>ISSN: 1079-9907</identifier><identifier>EISSN: 1557-7465</identifier><identifier>DOI: 10.1089/jir.2007.0097</identifier><identifier>PMID: 18439103</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Agonists (Biochemistry) ; Aminoquinolines - pharmacology ; Animals ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cell Survival - drug effects ; Culture Media, Conditioned - pharmacology ; Dendritic Cells - immunology ; Dosage and administration ; Drug therapy ; Health aspects ; Humans ; Interferon ; Interferon Type I - immunology ; Leukocytes, Mononuclear - drug effects ; Lung - drug effects ; Lung - pathology ; Melanoma - pathology ; Mice ; Neoplasms - pathology ; Oligodeoxyribonucleotides - pharmacology ; Quinolines - pharmacology ; Subcellular Fractions - drug effects ; Sulfonamides - pharmacology ; Toll-Like Receptor 7 - agonists ; Tumors</subject><ispartof>Journal of interferon & cytokine research, 2008-04, Vol.28 (4), p.253-263</ispartof><rights>COPYRIGHT 2008 Mary Ann Liebert, Inc.</rights><rights>(©) © 2008 Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-2b2502a3a6b1e5fe26fd48e4efee5d5757812caad8e418685e49e307f739fa4d3</citedby><cites>FETCH-LOGICAL-c397t-2b2502a3a6b1e5fe26fd48e4efee5d5757812caad8e418685e49e307f739fa4d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18439103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Inglefield, Jon R</creatorcontrib><creatorcontrib>Dumitru, Calin Dan</creatorcontrib><creatorcontrib>Alkan, Sefik S</creatorcontrib><creatorcontrib>Gibson, Sheila J</creatorcontrib><creatorcontrib>Lipson, Kenneth E</creatorcontrib><creatorcontrib>Tomai, Mark A</creatorcontrib><creatorcontrib>Larson, Chris J</creatorcontrib><creatorcontrib>Vasilakos, John P</creatorcontrib><title>TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN</title><title>Journal of interferon & cytokine research</title><addtitle>J Interferon Cytokine Res</addtitle><description>Antitumor effects of the toll-like receptor 7 (TLR7) agonist, 852A, were evaluated. Supernatants from human peripheral blood mononuclear cells (PBMC) stimulated with 852A inhibited the proliferation of tumor cell lines Hs294T and 769-P but had no effect on others (786-O and Caki-1). Because addition of 852A directly to the Hs294T cells did not inhibit their proliferation, the mechanism(s) of inhibition of tumor cell proliferation was investigated. Low nanomolar concentrations of 852A stimulated the production of interferon-alpha (IFN-alpha), IFN-inducible protein-10 (IP-10), interleukin-1 receptor antagonist (IL-1Ra), monocyte chemotactic protein-1 (MCP-1), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from human PBMCs. Cytokines stimulated by submicromolar concentrations of 852A were sufficient to inhibit Hs294T proliferation. At higher concentrations (3-30 microM), 852A induced the production of IL-12p70, IL-18, and IFN-gamma. PBMC cultures depleted of plasmacytoid dendritic cells (pDC) did not produce IFN-alpha, and their conditioned medium did not inhibit Hs294T proliferation. Anti-IFN-alpha/beta receptor (IFNAR) and anti-IFN-alpha antibodies partially abrogated Hs294T proliferation inhibition by 852A-stimulated PBMC supernatants, whereas separate neutralization of TRAIL, tumor necrosis factor-alpha (TNF-alpha, IFN-gamma, IFN-beta, or IFN-omega had no effect. In vivo, six doses of 852A administration significantly delayed the onset of lung colonies in a B16 melanoma model. Thus, the results demonstrate that the TLR7 agonist 852A inhibits in vitro proliferation of some tumor cells in a pDC-dependent and IFN-alpha-dependent manner and can delay tumor growth in vivo.</description><subject>Agonists (Biochemistry)</subject><subject>Aminoquinolines - pharmacology</subject><subject>Animals</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Culture Media, Conditioned - pharmacology</subject><subject>Dendritic Cells - immunology</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Interferon</subject><subject>Interferon Type I - immunology</subject><subject>Leukocytes, Mononuclear - drug effects</subject><subject>Lung - drug effects</subject><subject>Lung - pathology</subject><subject>Melanoma - pathology</subject><subject>Mice</subject><subject>Neoplasms - pathology</subject><subject>Oligodeoxyribonucleotides - pharmacology</subject><subject>Quinolines - pharmacology</subject><subject>Subcellular Fractions - drug effects</subject><subject>Sulfonamides - pharmacology</subject><subject>Toll-Like Receptor 7 - agonists</subject><subject>Tumors</subject><issn>1079-9907</issn><issn>1557-7465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFktGL1DAQxoso3nn66KsEBd-6TtKmSR6Xw9OFRUHO55BtJmeWNqlJ-7D_ventgiiC5CGZmd83TJKvql5T2FCQ6sPRpw0DEBsAJZ5U15RzUYu240_LGYSqlQJxVb3I-QgAnWTqeXVFZdsoCs11Nd_vvwliHmLweSaSsy3x4Yc_-NnHQKIj8zLGRHocBjKlOHiHyTzWfCYWJwwWw0xKPA0mj6Y_zdHbUgk2lR79ozITEyyZTxOSHdndfXlZPXNmyPjqst9U3-8-3t9-rvdfP-1ut_u6b5SYa3ZgHJhpTHegyB2yztlWYosOkVsuuJCU9cbYkqOykxxbhQ0IJxrlTGubm-r9uW-Z_OeCedajz-tAJmBcsu4UbTsB8F-QgaBSKlnAt3-Bx7ikUC6hWXl54EqxAr07Qw9mQO2Di3My_dpRb6lQXUcptIXa_IMqy-Lo-xjQ-ZL_Q1CfBX2KOSd0ekp-NOmkKejVC7p4Qa9e0KsXCv_mMutyGNH-pi-f3_wC1litdQ</recordid><startdate>200804</startdate><enddate>200804</enddate><creator>Inglefield, Jon R</creator><creator>Dumitru, Calin Dan</creator><creator>Alkan, Sefik S</creator><creator>Gibson, Sheila J</creator><creator>Lipson, Kenneth E</creator><creator>Tomai, Mark A</creator><creator>Larson, Chris J</creator><creator>Vasilakos, John P</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200804</creationdate><title>TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN</title><author>Inglefield, Jon R ; Dumitru, Calin Dan ; Alkan, Sefik S ; Gibson, Sheila J ; Lipson, Kenneth E ; Tomai, Mark A ; Larson, Chris J ; Vasilakos, John P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-2b2502a3a6b1e5fe26fd48e4efee5d5757812caad8e418685e49e307f739fa4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Agonists (Biochemistry)</topic><topic>Aminoquinolines - pharmacology</topic><topic>Animals</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Culture Media, Conditioned - pharmacology</topic><topic>Dendritic Cells - immunology</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Interferon</topic><topic>Interferon Type I - immunology</topic><topic>Leukocytes, Mononuclear - drug effects</topic><topic>Lung - drug effects</topic><topic>Lung - pathology</topic><topic>Melanoma - pathology</topic><topic>Mice</topic><topic>Neoplasms - pathology</topic><topic>Oligodeoxyribonucleotides - pharmacology</topic><topic>Quinolines - pharmacology</topic><topic>Subcellular Fractions - drug effects</topic><topic>Sulfonamides - pharmacology</topic><topic>Toll-Like Receptor 7 - agonists</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Inglefield, Jon R</creatorcontrib><creatorcontrib>Dumitru, Calin Dan</creatorcontrib><creatorcontrib>Alkan, Sefik S</creatorcontrib><creatorcontrib>Gibson, Sheila J</creatorcontrib><creatorcontrib>Lipson, Kenneth E</creatorcontrib><creatorcontrib>Tomai, Mark A</creatorcontrib><creatorcontrib>Larson, Chris J</creatorcontrib><creatorcontrib>Vasilakos, John P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of interferon & cytokine research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Inglefield, Jon R</au><au>Dumitru, Calin Dan</au><au>Alkan, Sefik S</au><au>Gibson, Sheila J</au><au>Lipson, Kenneth E</au><au>Tomai, Mark A</au><au>Larson, Chris J</au><au>Vasilakos, John P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN</atitle><jtitle>Journal of interferon & cytokine research</jtitle><addtitle>J Interferon Cytokine Res</addtitle><date>2008-04</date><risdate>2008</risdate><volume>28</volume><issue>4</issue><spage>253</spage><epage>263</epage><pages>253-263</pages><issn>1079-9907</issn><eissn>1557-7465</eissn><abstract>Antitumor effects of the toll-like receptor 7 (TLR7) agonist, 852A, were evaluated. Supernatants from human peripheral blood mononuclear cells (PBMC) stimulated with 852A inhibited the proliferation of tumor cell lines Hs294T and 769-P but had no effect on others (786-O and Caki-1). Because addition of 852A directly to the Hs294T cells did not inhibit their proliferation, the mechanism(s) of inhibition of tumor cell proliferation was investigated. Low nanomolar concentrations of 852A stimulated the production of interferon-alpha (IFN-alpha), IFN-inducible protein-10 (IP-10), interleukin-1 receptor antagonist (IL-1Ra), monocyte chemotactic protein-1 (MCP-1), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from human PBMCs. Cytokines stimulated by submicromolar concentrations of 852A were sufficient to inhibit Hs294T proliferation. At higher concentrations (3-30 microM), 852A induced the production of IL-12p70, IL-18, and IFN-gamma. PBMC cultures depleted of plasmacytoid dendritic cells (pDC) did not produce IFN-alpha, and their conditioned medium did not inhibit Hs294T proliferation. Anti-IFN-alpha/beta receptor (IFNAR) and anti-IFN-alpha antibodies partially abrogated Hs294T proliferation inhibition by 852A-stimulated PBMC supernatants, whereas separate neutralization of TRAIL, tumor necrosis factor-alpha (TNF-alpha, IFN-gamma, IFN-beta, or IFN-omega had no effect. In vivo, six doses of 852A administration significantly delayed the onset of lung colonies in a B16 melanoma model. Thus, the results demonstrate that the TLR7 agonist 852A inhibits in vitro proliferation of some tumor cells in a pDC-dependent and IFN-alpha-dependent manner and can delay tumor growth in vivo.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>18439103</pmid><doi>10.1089/jir.2007.0097</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1079-9907 |
| ispartof | Journal of interferon & cytokine research, 2008-04, Vol.28 (4), p.253-263 |
| issn | 1079-9907 1557-7465 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69146700 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Agonists (Biochemistry) Aminoquinolines - pharmacology Animals Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Culture Media, Conditioned - pharmacology Dendritic Cells - immunology Dosage and administration Drug therapy Health aspects Humans Interferon Interferon Type I - immunology Leukocytes, Mononuclear - drug effects Lung - drug effects Lung - pathology Melanoma - pathology Mice Neoplasms - pathology Oligodeoxyribonucleotides - pharmacology Quinolines - pharmacology Subcellular Fractions - drug effects Sulfonamides - pharmacology Toll-Like Receptor 7 - agonists Tumors |
| title | TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T17%3A56%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TLR7%20agonist%20852A%20inhibition%20of%20tumor%20cell%20proliferation%20is%20dependent%20on%20plasmacytoid%20dendritic%20cells%20and%20type%20I%20IFN&rft.jtitle=Journal%20of%20interferon%20&%20cytokine%20research&rft.au=Inglefield,%20Jon%20R&rft.date=2008-04&rft.volume=28&rft.issue=4&rft.spage=253&rft.epage=263&rft.pages=253-263&rft.issn=1079-9907&rft.eissn=1557-7465&rft_id=info:doi/10.1089/jir.2007.0097&rft_dat=%3Cgale_proqu%3EA179661104%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=215505992&rft_id=info:pmid/18439103&rft_galeid=A179661104&rfr_iscdi=true |